Oblique Therapeutics and Targovax enter collaboration to target mutant RAS cancers by combining their ONCOS and Abiprot™ platforms
Press Release June 29,2020 Oblique Therapeutics and Targovax enter collaboration to target mutant RAS cancers by combining their ONCOS and Abiprot™ platforms · Oblique Therapeutics and Targovax will jointly explore the feasibility and anti-cancer potential of merging their ONCOS and Abiprot[TM] technology platforms · ONCOS will be used to deliver Abiprot[TM] antibodies against hard-to-reach targets such as mutant RASGothenburg, Sweden & Oslo, Norway,June 29 2020 – Oblique Therapeutics today announces that it has entered into a collaboration agreement with Targovax ASA (OSE: TRVX)